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2080Background: Intracranial atherosclerotic disease is a common cause of stroke; its inci-
dence and prevalence vary widely by ethnicity. The aim of our study was to analyze
the recurrence rate of cerebrovascular events in patients with symptomatic and
asymptomatic intracranial stenosis (IS). Methods: We conducted a historical cohort
study including all patients admitted in our hospital for stroke or transient ischemic
attack (TIA) during 2011 and 2012 with information on intracranial circulation
(ultrasonography and/or computed tomography angiography). We identified pa-
tientswith symptomatic and asymptomatic IS and studied the recurrence of cerebro-
vascular events (TIA or ischemic stroke within the territory of the stenosis) for a
minimum follow-up period of 6 months after the diagnosis of IS. For the recurrence
rate estimation, patients with other potentially embolic diseases (in cervical arteries
or heart) were excluded. We calculated the rate of recurrence of cerebrovascular
events and performed Kaplan–Meier survival curves for symptomatic and asymp-
tomatic IS. Results: We investigated 1302 patients, mean age was 72.41 years (stan-
dard deviation 12.75). We identified 218 IS in 158 patients, 77 were symptomatic
and 141 were asymptomatic. The recurrence rate of cerebrovascular events was
12.32 per 100 patient-years, with amean time to recurrence of 1.73 months for symp-
tomatic intracranial stenosis (SIS) and .88 per 100 patient-years for asymptomatic IS
(P,.001).Conclusions: These results indicate a high risk of early recurrence of stroke
in the territory of a SIS, highlighting the importance of its early diagnosis and aggres-
sive treatment. Key Words: Intracranial atherosclerotic disease—intracranial
stenosis—recurrence rate—time to recurrence.
 2014 by National Stroke AssociationIntracranial atherosclerotic disease (ICAD) is character-
ized by the development, progression, and complication
of atherosclerotic lesions affecting large intracranial ar-
teries. ICAD is an important cause of stroke worldwide
and is associated with a high risk of recurrent stroke.1 ItsDepartment, Centro Hospitalar e Univer-
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Journal of Stroke and Cerebrovascprevalence varies largely by ethnicity, ranging from 8%-
10% in Caucasians to 50% in certain Asian populations.
Corresponding data on asymptomatic ICAD is scarce.
Population-based studies in Asia using transcranial
Doppler ultrasound found an asymptomatic ICAD prev-
alence of around 6%.2,3 In the metropolitan area of
Barcelona, a population-based study analyzing moderate
to high vascular risk population showed a prevalence of
asymptomatic ICAD of 8.6%.4
Apart from few large ICAD prospective studies, data
on the natural history of ICAD, especially on asymptom-
atic intracranial stenosis (AIS), is still limited.
Most studies examining the prognosis of ICAD perform
an analysis per patient. However, the treating physician
needs to make therapeutic decisions on the stroke risk
implicated with a specific artery. In particular, theular Diseases, Vol. 23, No. 8 (September), 2014: pp 2080-2084
RECURRENCE IN ICAD 2081decision on invasive therapeutic strategies directed to a
specific stenosis would benefit greatly from the knowl-
edge of the risk of recurrence assigned to that stenosis.
As such, a stenosis-based analysis would study the risk
attributed to each intracranial stenosis (IS), providing
valuable information for the selection of individualized
therapeutic strategies.
The purpose of this study was to investigate the
prognosis of symptomatic intracranial stenosis (SIS)
and asymptomatic intracranial stenosis (AIS) due to
atherosclerotic disease. We sought to perform a stenosis-
based analysis of the recurrence rate of stroke or
transient ischemic attack (TIA) in the territory of the
affected artery.Materials and Methods
We conducted a historical cohort study including all
patients admitted in our hospital for stroke or TIA from
January 2011 to December 2012. Local ethics committee’s
approval was obtained. We excluded patients without
information on intracranial circulation. We collected base-
line characteristics of the population through consultation
of patients’ clinical records. Hypertension was defined ac-
cording to the current guidelines of the European Society
of Cardiology5 and diabetes according to the recommen-
dations from the World Health Organization and the
American Diabetes Association.6 Dyslipidemia was
considered present when serum lipid concentration was
above the near-optimal level recommended by the Amer-
ican Association of Clinical Endocrinologists.7 Smoking
was considered when the patient was a current smoker
or had quit smoking in the past 6 months.
From this cohort we identified patients with IS. IS was
presumed as symptomatic when new neurologic signs
were related to an area of the brain supplied by the ste-
notic artery. Asymptomatic IS was defined as stenosis
not related to the current neurologic signs and with no
old infarction visible in neuroimaging in its respective
vascular territory. Patients with other etiologies for IS
such as vasculitis, vasospasm, arterial dissection, or
moyamoya disease were excluded.
The intracranial circulation was studied in all patients
by transcranial color-coded Doppler (TCCD) ultrasonog-
raphy. In subjects without transtemporal sonographic
window and a clinical suspicion of ICAD, a CT angiog-
raphy was performed.
TCCD ultrasonography was performed using a hand-
held 3MHz sector probe (General Electrics Logiq 7, Gen-
eral Electrics Healthcare, USA). The intracranial arteries
studied were intracranial internal carotid artery, M1 and
M2 segments of middle cerebral artery, A1 segment of
anterior cerebral artery, P1 and P2 segments of posterior
cerebral artery, basilar artery, and V4 segment of vertebral
artery. IS was classified as mild (,50%), moderate (50%-
80%), and high (80%) grade, according to peak systolicvelocities (Baumgartner criteria8). We considered .50%
stenosis as clinically significant arterial disease.
In the group of patients with IS, we determined recur-
rences of cerebrovascular events (TIA or ischemic stroke)
within the territory of the previously identified stenosis
until June 2013. This information was collected through
consultation of patients’ clinical records and telephone in-
terviews. We then performed a stenosis-based analysis,
calculating the recurrence rate of cerebrovascular events
for SIS and AIS. For this analysis, we excluded patients
with moderate to severe extracranial artery stenosis tan-
dem to a SIS and patients with known cardiac sources
of embolism.Statistical Analysis
Comparisons of baseline characteristics were made be-
tween patients without IS and patients with SIS and AIS,
respectively using independent samples t test (for contin-
uous variables) and c2 test (for categorical variables).
We performed Kaplan–Meier survival curves for SIS
and AIS and compared them using log-rank test. Values
of P , .05 were considered statistically significant.Results
Of the 1540 patients seen in our hospital for cerebrovas-
cular events during 2011 and 2012, we excluded 238 pa-
tients without information on intracranial circulation. In
the 1302 included patients, we identified 163 patients
with IS, corresponding to a total of 240 IS. Excluding non-
atheromatous causes of stenosis (3 patients with central
nervous system vasculitis, 1 patient with dissection of
intracranial vessels, and 1 patient with moyamoya dis-
ease), we found 158 patients with IS and 218 IS (77 were
symptomatic and 141 were asymptomatic; Fig 1).
Baseline characteristics and vascular risk factors of
subjects according to type of IS (symptomatic or asymp-
tomatic) are shown in Table 1. Patients with AIS were
older than patients with SIS (P 5 .018) and atrial fibrilla-
tion (AF) was more frequent in patients with AIS
(P 5 .032).
We calculated a frequency of SIS in our population of
5.76%.Study of the Recurrences of Cerebrovascular Events
To perform a stenosis-based analysis of the recurrences,
we excluded patients with AF (33 patients) and patients
with moderate to severe extracranial stenosis tandem to
the IS (8 patients). Thus, for the recurrence analysis, we
had 119 patients (corresponding to 171 IS): 72 (60.5%)
with SIS (corresponding to 107 stenosis) and 47 (39.5%)
with AIS (corresponding to 64 stenosis).
In the group of the 171 IS, we had a mean follow-up
time of 13.63 months (standard deviation 7.34). We found
15 ischemic events (stroke or TIA) in the territory of the
Figure 1. Study design. Abbreviations: AIS,
asymptomatic intracranial stenosis; IS, intracra-
nial stenosis; pts, patients; SIS, symptomatic
intracranial stenosis.
A. GOUVEIA ET AL.2082previously identified stenosis, 14 in SIS and 1 in AIS. We
obtained Kaplan–Meier survival curves showing the cu-
mulative probability of cerebrovascular event in the terri-
tory of a IS at any time point after baseline for SIS and AIS
(Fig 1). The recurrence rate for SIS was significantly
higher than for AIS: 12.32 of 100 patient-years versus .88
of 100 patient-years, P , .001, with a mean time to recur-
rence of 1.73 months for SIS.
Discussion
We have characterized a cohort of 158 patients with
ICAD and analyzed the cerebrovascular events recur-
rence in this group of patients.
Patients with AIS were older and had AF more
frequently than patients with SIS. It should be notedTable 1. Baseline characteristics of patients and comparison o
Baseline characteristics All patients (N 5 1302) WIS (N 5 11
Age, mean, (SD) 72.41 (12.75) 72.14 (12.9
Hypertension, n, (%) 892 (75.1) 755 (66.3
Diabetes, n, (%) 325 (27.4) 263 (23.1
Dyslipidemia, n, (%) 505 (42.5) 410 (40.0
Smoking, n, (%) 109 (9.2) 88 (7.7)
Atrial fibrillation, n, (%) 279 (23.5) 246 (21.6
Previous stroke, n, (%) 154 (13.0) 111 (9.7)
Abbreviations: AIS, asymptomatic intracranial stenosis; SIS, symptoma
cranial stenosis.
Values of p with statistical significance are presented in bold typeset.
Patients with nonatheromatous IS were not included in this analysis.
*P value for comparisons between patients without intracranial stenosis
yP value for comparisons between patients without intracranial stenosis
zP value for comparisons between patients with symptomatic and asymthat AIS was identified in patients who had an ischemic
event not related to IS. Therefore, it is expected that in
this group of patients, the proportion of other causes of
stroke, namely AF, is higher.
We found a prevalence of SIS in our population of
5.78%, which is slightly lower than the values described
for other Caucasian populations. For instance, in the
United States, ICAD is responsible for 8%-10% of
ischemic strokes in Caucasians.9 Nevertheless, asMazighi
et al10 suggested, in a study on autopsies of patients who
died as a consequence of ischemic or hemorrhagic stroke,
the real impact of ICAD on Caucasians may be greater
than expected. According to Asian studies, ICAD ac-
counts for 33%-50% of all strokes in China, 47% in
Thailand, 48% in Singapore, and 10%-25% in Korea.11f patients groups with symptomatic and asymptomatic IS
39) SIS (N 5 75) AIS (N 5 83) P* Py Pz
9) 72.67 (10.80) 76.59 (9.82) .686 ,.001 .018
) 59 (78.7) 74 (89.2) .413 .001 .083
) 28 (37.3) 32 (38.6) .030 .014 1.000
) 42 (56.0) 51 (61.4) .007 ,.001 .520
11 (14.7) 9 (10.8) .091 .425 .484
) 10 (13.3) 23 (27.7) .034 .428 .032
24 (32.0) 18 (21.7) ,.001 .007 .154
tic intracranial stenosis; SD, standard deviation; WIS, without intra-
and with symptomatic intracranial stenosis.
and with asymptomatic intracranial stenosis.
ptomatic intracranial stenosis.
Figure 2. Kaplan–Meier curves for the cumulative probability of an
ischemic stroke/TIA in the territory of a stenotic artery versus time. The
recurrence rates were 12.32 of 100 patient-years for SIS and .88 of 100
patient-years for AIS, P, .001. Abbreviations: AIS, asymptomatic intracra-
nial stenosis; SIS, symptomatic intracranial stenosis; TIA, transient
ischemic attack.
RECURRENCE IN ICAD 2083Data on the prognosis of ICAD are scarce, as opposed to
extracranial carotid artery disease, where natural history
has been extensively studied in several large carotid end-
arterectomy trials and other prospective studies.
In our population, we found a higher recurrence rate for
SIS than for AIS (12.32 per 100 patient-years and .88 per 100
patient-years, respectively). The survival plot (Fig 2)
clearly shows that the period of high recurrence risk in
SIS is in the first fewmonths after the ischemic event. These
data are of extreme importance for the treating physician
and is in line with data from previous observational12
and randomized studies. In fact, other studies addressing
this subject have performed an analysis per patient and
their results are close to ours. The largest prospective trial
on ICAD compared the natural history of ICAD in patients
treated with aspirin and warfarin—the Warfarin versus
Aspirin for Symptomatic Intracranial Disease (WASID) trial.13
In WASID trial, the annual recurrence rates of stroke in the
territory of a stenotic artery were 12% and 11% in the
aspirin and warfarin arms, respectively. More recently,
rigorous data on the influence of endovascular interven-
tions in the natural history of ICAD were provided by
the Stenting and Aggressive Medical Management for Prevent-
ing Recurrent stroke in Intracranial Stenosis trial. This trial
was a randomized controlled trial comparing best medical
treatment to best medical treatment plus angioplasty and
stent placement (percutaneous transluminal angioplasty
and stenting) for symptomatic .70% IS.14 The global
annual recurrence rate of stroke was 14.9% and 22.3% in
medical therapy and PTAS arms, respectively.15
Asymptomatic ICAD has been less well studied, espe-
cially in Caucasians. Our current understanding of the prev-alence and natural history of AIS comes, mostly, from
studies of patients who have SIS elsewhere or other neuro-
logic conditions, in whom AIS are concomitantly detected.
Thus, selection of such patients for the study of the prog-
nosis of asymptomatic ICAD possibly overestimates the
risk of cerebrovascular events attributed to AIS.16 InWASID
trial, AIS was detected in 27.3% of patients undergoing
magnetic resonance angiogram. The annual risk of cerebro-
vascular events in the territory of the AIS was 3.5%.17 Our
data confirm the low recurrence rates attributable to AIS.
As these data suggest, ICAD, in the form of SIS, carries
one of the highest rates of stroke recurrency in vascular
neurology, with a greater propensity for very early recur-
rences. Conversely, asymptomatic ICAD appears to repre-
sent a relatively benign condition with low annual
incidences of stroke and TIA.
To study the effective recurrence rates of IS, we excluded
patients with other embolic diseases, namely extracranial
tandem disease and cardioembolic emboligenous pathol-
ogies, potentially capable of causing ischemic events virtu-
ally impossible to distinguish from those caused by IS. We
believe this allowed a more accurate estimation of recur-
rence rates directly attributable to each stenosis.
There are some limitations in our study. First, it is a
single-center, historical cohort study. Nonetheless, consid-
ering the hard endpoints analyzed it is unlikely to suffer
from loss of information. Second, patients’ ongoing treat-
ments were not analyzed. This may have led to underesti-
mation of the recurrence rates, especially of SIS. However, it
should be noted that all patients were followed in a single
tertiary center with homogeneous treatment strategies, thus
potentiating an estimation of ‘‘real-life’’ recurrence rates.
Moreover, the diagnosis of IS was mostly based in TCCD,
which proved to reliably exclude the presence of 50%-
99% IS, with a negative predictive value of 86%.18 CT angi-
ography was only performed in selected cases of clinical
suspicion. As such, some patients (238, 15.45%) did not
have data on intracranial circulation and were excluded.
This could have led to a slight underestimation of the prev-
alence of IS among our population. Notwithstanding, it
should also be taken under consideration that these were
patients with low level of clinical suspicion of IS; therefore,
this limitation is not expected to significantly impair the re-
sults obtained.
To conclude, the present study indicates a high risk of
early recurrence in patients with SIS, as opposed to AIS,
which appears to have a more benign prognosis. Recur-
rence rates were estimated for each stenosis and
excluding other potentially emboligenous diseases; thus,
providing more precise information to plan future indi-
vidualized therapeutic interventions.
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